Abstract: The invention provides a Hemsleya chinensis cytochrome oxidase HcCYP87D19 gene, and the sequence of the gene is shown in SEQ NO: 1. This invention constructs a transgenic Saccharomyces cerevisiae engineering bacteria co-transfected with Hemsleya cathayensis cytochrome oxidase HcCYP87D19 and HcCYP81Q58, the bacteria can produce a variety of cucurbitacin intermediates including 11-Carbonyl-cucurbita-5,23-diene-3?,16a,20,25-tetrol (6), 11-Carbonyl-cucurbita-5,23-diene-3?,16?,20,23-tetrol (6b), 11-Carbonyl-cucurbita-5,23-diene-16?,20,25-triol-3-one (6a), 11-Carbonyl-cucurbita-5,24-diene-16?,20,23-triol-3-one (6c), it provides a source for cucurbitacin production.

Abstract: The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.

Abstract: A flip-folding lift desk includes: a support base, the bottom surface of the support base having at least three support members, the top surface of the support base having a connection seat extending in a direction away from the support members; a lift assembly arranged to rise and fall along its length direction, one end of the lift assembly being rotatably connected to the connection seat, so that the lift assembly can switch between two states in the length direction, including one in which the lift assembly is perpendicular to the support base, and the other in which the lift assembly is parallel to the support base; a rotation locking assembly comprising a fixed disk, a locking block, a rotating disk, a torsion spring, and a driving block; and a top assembly connected to the rotating disk on the rotation locking assembly.

Abstract: The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.

Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.

Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.

Abstract: The present invention provides compositions and methods comprising interleukin-2 (TL-2) polypeptide conjugates. Also described are IL-2 conjugates for the treatment of diseases or conditions including cancer.

Abstract: A flip-folding lift desk includes: a support base, the bottom surface of the support base having at least three support members, the top surface of the support base having a connection seat extending in a direction away from the support members; a lift assembly arranged to rise and fall along its length direction, one end of the lift assembly being rotatably connected to the connection seat, so that the lift assembly can switch between two states in the length direction, including one in which the lift assembly is perpendicular to the support base, and the other in which the lift assembly is parallel to the support base; a rotation locking assembly comprising a fixed disk, a locking block, a rotating disk, a torsion spring, and a driving block; and a top assembly connected to the rotating disk on the rotation locking assembly.

Abstract: The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.

Abstract: The present invention provides methods for targeting interleukin-10 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-10 (IL-10) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-10 receptor.

Abstract: Disclosed herein are methods and compositions for generation of cell lines to promote unnatural amino acid-containing protein production using genome engineering technology.

Abstract: Controlling an image element associated with a distance from an energy measuring device, in a reflected energy measurement system involves producing at least one signal for controlling a common visible characteristic of the image element, in response to a plurality of signals representing respective intensities of reflected energy at respective different frequencies, measured at the energy measuring device at a time corresponding to the distance.

Abstract: Controlling an image element associated with a distance from an energy measuring device, in a reflected energy measurement system involves producing at least one signal for controlling a common visible characteristic of the image element, in response to a plurality of signals representing respective intensities of reflected energy at respective different frequencies, measured at the energy measuring device at a time corresponding to the distance.

Abstract: The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory diseases, mast cell mediated disease and transplant rejection.

Abstract: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection.

Abstract: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection.

Abstract: The present invention provides novel purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection.

Abstract: The present invention provides novel purine and imidazopyridine derivatives useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection.

Abstract: The present invention relates to compounds of formula (I): (I) their pharmacologically acceptable salts, or solvates and hydrates, and their prodrugs, respectively, and to pharmaceutical compositions containing the same as active ingredient. These novel compounds are especially useful in the treatment of cancer.